Clinical Trial

Study of High Density Lipoprotein Function in Type 1 Diabetic Patients With Nephropathy

Study acronym: DID&NEPHRO
Unknown
View on ClinicalTrials.gov →
Record status
This record was last updated July 19, 2024 (before its estimated April 2026 completion). Its status may not reflect the trial's current state.
Summary
A number of arguments suggest that the deterioration in high density lipoproteins (HDL) functioning may worsen with the development of nephropathy during type 1 diabetes (T1D). The objective of this study will be to investigate to what extent nephropathy in T1D patients in the microalbuminuria and macroalbuminuria stages, compared to T1D patients without nephropathy, is associated with an alteration in HDL functionality and changes in HDL size and composition (lipids with detailed study of phosphates and sphingolipids, main lipoproteins, inflammatory markers).
Protocol Amendment History 1 change
critical Trial status changed: Recruiting → Unknown 2026-08-02
Trial Details
NCT Number NCT03512132
Lead Sponsor Centre Hospitalier Universitaire Dijon
Conditions Type 1 Diabetes
Enrollment 200 participants
Start Date 2018-04-24
Primary Completion 2026-04 (estimated)
Study Completion 2026-04 (estimated)
Updated on ClinicalTrials.gov 2024-07-19